Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.58 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3161223 | 0.88 | PTGS2 (0.65) | PTGS2PTGS1SYKATR | |
| SCHEMBL3153521 | 0.80 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL3161824 | 0.80 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL5675573 | 0.75 | PTGS2 (0.98) | PTGS2PTGS1 | |
| SCHEMBL5675609 | 0.74 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL3161588 | 0.73 | PTGS2 (0.58) | PTGS2PTGS1 | |
| SCHEMBL3168024 | 0.73 | PTGS2 (0.58) | PTGS2PTGS1 | |
| SCHEMBL3748251 | 0.72 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL3158145 | 0.72 | PTGS2 (0.59) | PTGS2PTGS1SYK | |
| SCHEMBL13248616 | 0.72 | GABBR2 (0.65) | PTGS2PTGS1SYKATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | DPYD, NUDT1, HPRT1 | PTGS2 2711/4885PTGS1 2007/4885SYK 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.